American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for ... (ion sessions all of which could contribu...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression

Date:9/30/2008

ion sessions, all of which could contribute to a worse outcome, Lichtman said.

It's also possible that biological changes associated with depression such as reduced heart rate variability and increases in blood factors that encourage clot formation could increase risk, the statement said.

Other recommendations in the statement include:

-- Patients who have depressive symptoms should be evaluated by a

professional qualified in diagnosing and managing depression, and should

be screened for other psychiatric disorders, such as anxiety.

-- Treatment options include cognitive behavioral therapy, physical

activity, cardiac rehabilitation, antidepressant drugs or combinations

of those treatments.

-- Selective serotonin reuptake inhibitor (SSRI) treatment soon after a

heart attack is considered safe, relatively inexpensive and may be

effective for treating depression.

-- Routine screening for depression in coronary heart disease patients

should be done in multiple settings, including the hospital,

physician's office, clinic and cardiac rehabilitation center, to

avoid missing the opportunity to effectively treat depression in cardiac

patients and improve physical health outcomes.

-- Coordination of care between health providers is essential for patients

with combined medical and psychiatric diagnoses.

"Depression and heart disease seem to be very much intertwined," Lichtman said. "You can't treat the heart in isolation from the patient's mental health.

"There is no direct evidence yet that treating depression improves coronary heart disease outcomes, but plenty of evidence shows that having depression worsens those outcomes. By understanding the prevalence of depression and learning more about the subgroups of heart patients at particular risk of depression, we can begin to understand the best ways
'/>"/>

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. American Heart Association Journal Report: Miniaturized Heart Pumps May Be Effective for Children Awaiting Transplant
2. American Heart Association Journal Report: Surgical Residents Perform Heart Surgery as Effectively as Staff Surgeons
3. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
4. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
8. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
9. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
10. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
11. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008

Post Your Comments:

(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...

(Date:12/16/2009)... SAN DIEGO, Dec. 16 Optimer Pharmaceuticals, ... present at the 28th Annual J.P. Morgan Healthcare ... San Francisco on Wednesday, January 13, 2010. Michael ... will present at 2:30 p.m. Pacific Time (5:30 ... ,, A live audio webcast of this presentation ...

(Date:12/16/2009)... -- , - Studies ... and Published* in November 2009, in the Official ... Reveal new Benefits for,Peptan(TM) in Osteoporosis Prevention , ... concerns regarding long-term bone health,Rousselot has carried out, ... an oral intake of Peptan(TM) may have a ...

Breaking Medicine Technology:Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2 Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3 Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2 Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health 2 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 1 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 2 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 3 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 4 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 5 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 6 Daiichi Sankyo and Lilly Receive U S FDA Approval for Effient 28TM 29 51376 7 Mount Sinais Dr Benjamin tenOever to be honored by White House 9211 1 Mount Sinais Dr Benjamin tenOever to be honored by White House 9211 2 Mount Sinais Dr Benjamin tenOever to be honored by White House 9211 3 PTs say proper fit and use of walking aids can prevent fall related injuries in elderly 51371 1 PTs say proper fit and use of walking aids can prevent fall related injuries in elderly 51371 2

[0] Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression [0] Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference [0] Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health

... Tezampanel Development Targeting Chronic Pain Conditions; Compound ... Trial for Acute Migraine -, LA JOLLA, Calif., ... today announced that it has initiated a,Phase I multiple ... of tezampanel given as a subcutaneous injection to,healthy male ...

... Proprietary Artificial, Intelligence-Based Drug Discovery Platform and Novel Drug Candidates ... ... -Initial Compounds Demonstrate Promising In Vitro Activity Against, ... Aug. 27 Upstream Biosciences,Inc. (OTC Bulletin Board: UPBS) today announced ...

Other Medicine Technology:TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 2 TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 3 TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 4 Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 2 Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 3 Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 4 Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 5 Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 6 Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 7

TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases

(Date:12/16/2009)... Dec. 16 Dale Buchanan, owner of Supreme ... have a weight loss contest for his students in the ... students are not competing for their own prize or against ... for the Tri County Humane Society in Boca ... mine loses between January 4 and February 28, 2010 I ...

(Date:12/16/2009)... in the ,70s, study finds , , TUESDAY, Dec. 15 ... the United States than it was more than 30 ... Researchers compared National Health and Nutrition Examination Survey data ... 1972 and from 8,339 black and white participants from ... years old. , The prevalence of myopia increased from ...

(Date:12/16/2009)... interval lessens complication risks , , TUESDAY, Dec. 15 (HealthDay News) ... such a profound impact on your life that you just ... new study suggests that you might want to wait at ... than 11 months could be even better. , The ... than six months, the chances of the baby dying, being ...

(Date:12/16/2009)... money to help clothe children in need. , ... ... cleaner Dryclean USA Florida , along with Atlantic Awnings of Miami, ... help clothe children in need by collecting funds on behalf of ... cards, with delivery of their clean clothes, and pamphlets requesting donations ...

(Date:12/16/2009)... 2009) Unisense FertiliTech A/S has received a further 1.6 million Euro ... the EmbryoScope™ Embryo Monitoring System in order to meet the rapidly ... by LD Pensions and Unisense A/S that continue to own each ... ... (PRWEB) December 16, 2009 -- Unisense FertiliTech A/S has received a ...

Breaking Medicine News(10 mins):Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2 Health News:For Babies' Sake, Pregnancy Spacing Matters 2 Health News:For Babies' Sake, Pregnancy Spacing Matters 3 Health News:Pay a Dollar, Dress a Child: Helping Struggling Families with Small Donations 2 Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2

[0] Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter [0] Nearsightedness on the Increase [0] For Babies' Sake, Pregnancy Spacing Matters [0] Pay a Dollar, Dress a Child: Helping Struggling Families with Small Donations [0] Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device

... product revenue and reduced expenses continue to drive solid cash ... (Nasdaq: WCRX ) today announced its results for ... in the quarter ended December 31, 2008 totaled $242.5 million, ... for the year ended December 31, 2008 totaled $938.1 million, ...

... Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical ... company,s premier dental pharmaceutical product. OraVerse is the ... accelerates the return to normal sensation and function ... and unnecessary lingering soft tissue anesthesia following routine ...

... Feb. 27 /PRNewswire-Asia/ -- GE Healthcare, a,leading ... suite of,Centricity solutions targeted for hospitals and ... and advanced clinical capabilities,the suite provides the ... acquisition from Dynamic Imaging. , ...

... -- endorsed by,NaturalNews, Organic Consumers Association, Life Extension ... freedom groups --,calls for an end to FDA ... Its ten provisions also call for full income ... to the psychiatric drugging of,children, the end of ...

... Nursing Productivity in the Treatment of Renal Disease , ... ... 2009 -- iSirona®, an innovative provider of data automation solutions ... agreement with NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer ...

... Healthy Directions, LLC, is proud to announce the launch of searchjointpain.com, a ... conditions and solutions. , ... Potomac, MD (PRWEB) February 27, 2009 -- ... to announce the launch of searchjointpain.com , a new informational Web ...

Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 Video: Novalar Announces the Launch of OraVerse(TM) the First Dental Anesthesia Reversal Agent GE Healthcare Extends Leading Web-Based Imaging Solutions to Asia Health Freedom Groups Join in Launch of Grassroots Health Revolution Petition at HealthRevolutionPetition.org iSirona Signs Reference Selling Agreement with NxStage Healthy Living Network Announces Launch of New Joint Pain Web Site

... storage of blood plasma in full accordance ... to operating temperatures and performance means that ... freezer you will minimise bag cracking normally ... an additional benefit is reduced thawing time. ...

Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost times....

Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...

... complying with Australian Standard AS3864-1997 suitable to ... grey colorbond steel with a powder coated ... 40-litre capacity polished stainless steel compartment. Lid ... a heated top fascia. A removable chrome ...

Medicine Products:

Labcold™ Fresh Frozen Plasma Freezer i.Series Plasma Storage Freezer (-30C)Plasma Blast Chest Freezer -50C Chest-Style Plasma Freezer

American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for ...(ion sessions all of which could contribu...),Health